Receptor activator of nuclear ??B ligand and osteoprotegerin: where are we now and what about future treatment uses?

[1]  Colin R Dunstan,et al.  A Single‐Dose Placebo‐Controlled Study of AMG 162, a Fully Human Monoclonal Antibody to RANKL, in Postmenopausal Women , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[2]  P. Cohen.  Self-arthrocentesis in a man with joint pain. , 2004, Arthritis and rheumatism.

[3]  E. Schwarz,et al.  RANK Signaling Is Not Required for TNFα‐Mediated Increase in CD11bhi Osteoclast Precursors but Is Essential for Mature Osteoclast Formation in TNFα‐Mediated Inflammatory Arthritis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  L. Frommelt,et al.  Receptor activator of nuclear factor κB ligand is expressed in resident and inflammatory cells in aseptic and septic prosthesis loosening , 2003, Scandinavian journal of rheumatology.

[5]  Mary L Bouxsein,et al.  The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. , 2003, The New England journal of medicine.

[6]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[7]  E. Schwarz,et al.  Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. , 2003, The Journal of clinical investigation.

[8]  J. Risteli,et al.  Two year randomized controlled trial of etidronate in rheumatoid arthritis: changes in serum aminoterminal telopeptides correlate with radiographic progression of disease. , 2003, The Journal of rheumatology.

[9]  Steven W. Martin,et al.  A Phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases , 2003, Cancer.

[10]  E. Schwarz,et al.  Differences in the cytokine profiles associated with prostate cancer cell induced osteoblastic and osteolytic lesions in bone , 2003 .

[11]  L. Joosten,et al.  Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis. , 2002, Arthritis and rheumatism.

[12]  T. Martin,et al.  Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. , 2002, The American journal of pathology.

[13]  Kirk E. Smith,et al.  Recombinant Adeno-Associated Virus-Mediated Osteoprotegerin Gene Therapy Inhibits Wear Debris-Induced Osteolysis , 2002, The Journal of bone and joint surgery. American volume.

[14]  G. Kollias,et al.  Tumor necrosis factor alpha-mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerin. , 2002, Arthritis and rheumatism.

[15]  E. Schwarz,et al.  Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis , 2002, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[16]  Y. Iwamoto,et al.  Fibroblasts from the inner granulation tissue of the pseudocapsule in hips at revision arthroplasty induce osteoclast differentiation, as do stromal cells , 2002, Annals of the rheumatic diseases.

[17]  A. Boskey,et al.  In Vivo RANK Signaling Blockade Using the Receptor Activator of NF‐κB:Fc Effectively Prevents and Ameliorates Wear Debris‐Induced Osteolysis via Osteoclast Depletion Without Inhibiting Osteogenesis , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[18]  A R Pettit,et al.  TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. , 2001, The American journal of pathology.

[19]  P. Kostenuik,et al.  Printed in U.S.A. Copyright © 2001 by The Endocrine Society OPG and PTH-(1–34) Have Additive Effects on Bone Density and Mechanical Strength in Osteopenic Ovariectomized Rats , 2022 .

[20]  D. Howie,et al.  The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. , 2001, The Journal of bone and joint surgery. British volume.

[21]  P. Kostenuik,et al.  Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. , 2001, Cancer research.

[22]  A. Mizokami,et al.  Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. , 2001, The Journal of clinical investigation.

[23]  Paul J. Williams,et al.  Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. , 2001, Cancer research.

[24]  A. Nakanishi,et al.  The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  S. Takeshita,et al.  TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. , 2000, The Journal of clinical investigation.

[26]  E. Schwarz,et al.  Breakthrough in bone: the molecular mechanism of osteoclast/osteoblast coupling revealed , 2000 .

[27]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[28]  T. Martin,et al.  Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. , 2000, Arthritis and rheumatism.

[29]  P. Kostenuik,et al.  Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. , 2000, Cancer research.

[30]  Kozo Nakamura,et al.  Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[31]  S. Goldring,et al.  Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. , 2000, Arthritis and rheumatism.

[32]  Sundeep Khosla,et al.  The Roles of Osteoprotegerin and Osteoprotegerin Ligand in the Paracrine Regulation of Bone Resorption , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[34]  W. Dougall,et al.  RANK is essential for osteoclast and lymph node development. , 1999, Genes & development.

[35]  S. Morony,et al.  OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis , 1999, Nature.

[36]  S. Morony,et al.  osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. , 1998, Genes & development.

[37]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[38]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[39]  H. Rubash,et al.  The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. , 1997, Clinical orthopaedics and related research.

[40]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[41]  W. Harris,et al.  The problem is osteolysis. , 1995, Clinical orthopaedics and related research.

[42]  S. Ralston,et al.  Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. , 1989, Annals of the rheumatic diseases.

[43]  E. Schwarz,et al.  Systemic tumor necrosis factor α mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor α–transgenic mice , 2004 .